Infinity Pharmaceuticals, Inc.
INFI
INFI was delisted on the 13th of September, 2023.
93 hedge funds and large institutions have $38.6M invested in Infinity Pharmaceuticals, Inc. in 2022 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 17 increasing their positions, 37 reducing their positions, and 15 closing their positions.
340% more call options, than puts
Call options by funds: $471K | Put options by funds: $107K
4% less funds holding
Funds holding: 97 → 93 (-4)
27% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 15
53% less capital invested
Capital invested by funds: $82.5M → $38.6M (-$43.8M)
54% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 37
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$706K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$334K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$315K |
| 4 |
VOYA Investment Management
Atlanta,
Georgia
|
+$182K |
| 5 |
Morgan Stanley
New York
|
+$176K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.73M |
| 2 |
Millennium Management
New York
|
-$818K |
| 3 |
D.E. Shaw & Co
New York
|
-$555K |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$339K |
| 5 |
CC
Callan Capital
La Jolla,
California
|
-$329K |
INFI Hedge Fund Activity: Q1 2022 in Review
93 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Infinity Pharmaceuticals, Inc. (INFI) for Q1 2022, worth a combined $38.6M — down 53% from $82.5M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of INFI and 11 opened new positions — a net loss of 4 holders — while 37 trimmed existing stakes and 17 added.
The largest buyer was Renaissance Technologies, adding an estimated $706K. The largest seller was Point72 Asset Management, exiting entirely with an estimated $1.73M sold.
- 93 institutional investors held Infinity Pharmaceuticals, Inc. (INFI) as of Q1 2022, down from 97 in Q4 2021.
- Funds reported $38.6M of Infinity Pharmaceuticals, Inc. stock for Q1 2022, down 53% quarter-over-quarter.
- 11 funds opened new Infinity Pharmaceuticals, Inc. positions in Q1 2022 and 15 closed out, a net change of -4 holders.
- The largest Infinity Pharmaceuticals, Inc. buyer in Q1 2022 was Renaissance Technologies, an estimated $706K added.
- The largest Infinity Pharmaceuticals, Inc. seller in Q1 2022 was Point72 Asset Management, an estimated $1.73M sold.
Based on aggregated 13F filings for Q1 2022.